Director Appointment

Company Announcement
5 December 2018
1

DIRECTOR APPOINTMENT

Cancer diagnostics company, Pacific Edge Limited (NZX:PEB), is pleased to announce the
appointment of Sarah Park as an Independent Director; effective from 6 December 2018.

Sarah will also chair the Audit and Risk Committee of the Board.

Chairman of Pacific Edge, Chris Gallaher; said “Sarah brings international corporate finance
experience to our Board after a professional career with Pricewaterhouse Coopers in New Zealand
and HSBC Investment Bank in London.

She has also had a lead role in venture capital raisings in Asia, the Middle East and Europe for US
based biopharmaceutical companies, through to a planned listing on the AIM Exchange in London
and has been closely involved in the management of a Family Office Investment Fund in a private
capacity.

Sarah has now commenced her corporate governance career and is an Independent Director of a
number of private companies and foundations, including Hawkes Bay Airport where she also chairs
the Audit and Finance Committee.

Sarah’s appointment strengthens the skills mix around our Board table as the Company continues
its to progress the commercialisation of its technology in the USA and other targeted markets “.

Sarah resides in the Hawkes Bay.


Ends



For more information contact:
David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800


OVERVIEW www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery
and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. The company
is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central
laboratories in New Zealand and the USA. The company’s products have been tested and validated in international
multi-centre clinical studies.

Pacific Edge has four proprietary, novel, accurate, molecular diagnostic products in-market providing actionable results,
and better detection and management of urothelial cancer. Cxbladder Triage, Detect and Monitor are available through
the company’s dedicated CLIA-certified laboratories for customers in New Zealand, Australia, Singapore and the USA.
Cxbladder Resolve launched in New Zealand in December 2016.

ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to
accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more
extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of
patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who
have a low probability of having urothelial carcinoma.

Company Announcement
5 December 2018
2


ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of
a patients’ urine. Cxbladder Detect was launched in 2013 in the USA and is commercially available in New Zealand,
Australia and the USA as a Laboratory Developed Test (LDT) from the company’s CLIA certified laboratories. Cxbladder
Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective
adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists, is a proprietary, non-invasive, molecular
diagnostic test that combines genomic biomarkers measured from a small quantity of a patient’s urine, with patient
specific clinical factors to better monitor bladder cancer patients for recurrence. Bladder cancer has a recurrence rate
of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of
urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial
carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of
patients for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com
Cxbladder Resolve is a proprietary, non-invasive, molecular diagnostic test that combines genomic biomarkers
measured from a small quantity of a patient’s urine, with patient characteristics for the identification of patients who
are likely to have aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary
evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist
clinicians by accurately identifying patients with a high probability of having high grade or late stage bladder cancer, for
whom alternative or expedited treatment options may be warranted, or who can be prioritised for further investigation
in high throughput settings.

Refer to www.cxbladder.com for more information.